MDT · Medtronic PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.02B | $8.96B | $8.58B | $8.40B | $8.29B | $7.92B | $7.98B | $8.09B | $7.70B | $7.58B |
| Cost of Revenue | $3.26B | $3.06B | $3.00B | $2.95B | $2.78B | $2.76B | $2.76B | $2.78B | $2.63B | $2.54B |
| Gross Profit | $5.76B | $5.90B | $5.58B | $5.46B | $5.51B | $5.15B | $5.22B | $5.31B | $5.07B | $5.05B |
| R&D | $722.00M | $754.00M | $726.00M | $697.00M | $675.00M | $676.00M | $698.00M | $695.00M | $668.00M | $676.00M |
| SG&A | $2.96B | $2.96B | $2.81B | $2.76B | $2.72B | $2.65B | $2.69B | $2.67B | $2.61B | $2.62B |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $308.00M | $262.00M | $748.00M | - | - | $662.00M | - | - | $672.00M | - |
| Operating Income | $1.46B | $1.69B | $1.45B | $1.59B | $1.65B | $1.28B | $1.34B | $1.48B | $1.27B | $1.40B |
| Interest Expense | $181.00M | $181.00M | $176.00M | $180.00M | $188.00M | $148.00M | $180.00M | $188.00M | $148.00M | $118.00M |
| Income Tax | $254.00M | $215.00M | $255.00M | $281.00M | $237.00M | $220.00M | $402.00M | $135.00M | $400.00M | $959.00M |
| Net Income | $1.14B | $1.37B | $1.04B | $1.27B | $1.29B | $1.04B | $909.00M | $1.32B | $791.00M | $427.00M |
| EPS - Basic | $0.89 | $1.07 | $0.81 | $0.99 | $1.01 | $0.81 | $0.68 | $0.99 | $0.59 | $0.32 |
| EPS - Diluted | $0.89 | $1.07 | $0.81 | $0.99 | $1.01 | $0.80 | $0.68 | $0.99 | $0.59 | $0.32 |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.15B | $1.28B | $1.27B | $2.22B | $1.24B | $1.31B | $1.28B | $1.62B | $1.34B | $1.54B |
| Accounts Receivable | $6.36B | $6.39B | $6.26B | $6.51B | $6.12B | $6.01B | $6.13B | $5.97B | $5.81B | $6.00B |
| Inventory | $6.31B | $6.16B | $5.89B | $5.48B | $5.61B | $5.41B | $5.22B | $5.73B | $5.67B | $5.29B |
| Accounts Payable | $2.57B | $2.58B | $2.56B | $2.45B | $2.29B | $2.29B | $2.41B | $1.99B | $2.24B | $2.66B |
| Current Assets | $24.07B | $24.00B | $23.22B | $23.81B | $22.51B | $21.95B | $21.93B | $22.51B | $21.87B | $21.68B |
| Total Assets | $91.48B | $91.35B | $90.97B | $91.68B | $89.97B | $89.75B | $89.98B | $90.84B | $90.78B | $90.95B |
| Current Liabilities | $9.49B | $9.94B | $11.53B | $12.88B | $11.84B | $10.29B | $10.79B | $9.79B | $9.05B | $9.05B |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $42.29B | $42.49B | $42.84B | $43.42B | $40.36B | $41.59B | $39.56B | $38.84B | $39.41B | $39.28B |
| Stockholders' Equity | $48.98B | $48.65B | $47.89B | $48.02B | $49.39B | $47.95B | $50.21B | $51.79B | $51.18B | $51.48B |
| Retained Earnings | $32.30B | $32.07B | $31.61B | $31.48B | $31.32B | $30.55B | $30.40B | $30.66B | $30.27B | $30.39B |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | $1.09B | - | - | $986.00M | - | - | $875.00M | - |
| Investing Cash Flow | - | - | ($719.00M) | - | - | ($259.00M) | - | - | ($539.00M) | - |
| Financing Cash Flow | - | - | ($1.38B) | - | - | ($731.00M) | - | - | ($501.00M) | - |
| CapEx | - | - | $504.00M | - | - | $520.00M | - | - | $354.00M | - |
| Free Cash Flow | - | - | $584.00M | - | - | $466.00M | - | - | $521.00M | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 63.8% | 65.8% | 65.0% | 64.9% | 66.5% | 65.1% | 65.4% | 65.6% | 65.9% | 66.6% |
| Operating margin | 16.2% | 18.8% | 16.8% | 19.0% | 19.9% | 16.1% | 16.8% | 18.3% | 16.5% | 18.5% |
| EBITDA margin | 19.7% | 21.7% | 25.6% | - | - | 24.5% | - | - | 25.2% | - |
| Net margin | 12.7% | 15.3% | 12.1% | 15.1% | 15.6% | 13.2% | 11.4% | 16.3% | 10.3% | 5.6% |
| Free cash flow margin | - | - | 6.8% | - | - | 5.9% | - | - | 6.8% | - |
| FCF / Net income | - | - | 0.56 | - | - | 0.45 | - | - | 0.66 | - |
| R&D / Revenue | 8.0% | 8.4% | 8.5% | 8.3% | 8.1% | 8.5% | 8.7% | 8.6% | 8.7% | 8.9% |
| SG&A / Revenue | 32.8% | 33.1% | 32.7% | 32.8% | 32.8% | 33.5% | 33.6% | 33.0% | 33.9% | 34.5% |
| Effective tax rate | 18.2% | 13.5% | 19.7% | 18.1% | 15.5% | 17.4% | 30.7% | 9.3% | 33.6% | 69.2% |
| Return on assets | 1.2% | 1.5% | 1.1% | 1.4% | 1.4% | 1.2% | 1.0% | 1.5% | 0.9% | 0.5% |
| Return on equity | 2.3% | 2.8% | 2.2% | 2.6% | 2.6% | 2.2% | 1.8% | 2.6% | 1.5% | 0.8% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.54 | 2.42 | 2.01 | 1.85 | 1.90 | 2.13 | 2.03 | 2.30 | 2.42 | 2.39 |
| Quick ratio | 1.87 | 1.80 | 1.50 | 1.42 | 1.43 | 1.61 | 1.55 | 1.71 | 1.79 | 1.81 |
| Cash ratio | 0.12 | 0.13 | 0.11 | 0.17 | 0.10 | 0.13 | 0.12 | 0.17 | 0.15 | 0.17 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 8.1x | 9.3x | 8.2x | 8.9x | 8.8x | 8.6x | 7.4x | 7.9x | 8.6x | 11.9x |
| Equity multiplier | 1.87 | 1.88 | 1.90 | 1.91 | 1.82 | 1.87 | 1.79 | 1.75 | 1.77 | 1.77 |
| Liabilities / Assets | 0.46 | 0.47 | 0.47 | 0.47 | 0.45 | 0.46 | 0.44 | 0.43 | 0.43 | 0.43 |
| Efficiency | ||||||||||
| Asset turnover | 0.10 | 0.10 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | 0.08 |
| Inventory turnover | 0.52 | 0.50 | 0.51 | 0.54 | 0.50 | 0.51 | 0.53 | 0.49 | 0.46 | 0.48 |
| Days sales outstanding | 257d | 260d | 266d | 283d | 269d | 277d | 280d | 269d | 275d | 289d |
| Days inventory outstanding | 706d | 734d | 716d | 678d | 737d | 716d | 690d | 751d | 787d | 762d |
| Days payable outstanding | 288d | 308d | 311d | 303d | 300d | 303d | 319d | 261d | 311d | 383d |
| Cash conversion cycle | 676d | 687d | 672d | 658d | 706d | 690d | 651d | 759d | 751d | 667d |
| Valuation | ||||||||||
| P / E | 113.3x | 87.5x | 114.7x | 85.0x | 89.3x | 98.4x | 117.3x | 87.4x | 149.6x | 284.2x |
| P / B | 2.7x | 2.5x | 2.5x | 2.3x | 2.3x | 2.1x | 2.1x | 2.2x | 2.3x | 2.4x |
| P / S | 14.4x | 13.5x | 13.9x | 12.9x | 14.0x | 12.9x | 13.3x | 14.2x | 15.3x | 16.0x |
| EV / EBITDA | 72.8x | 61.3x | 54.0x | - | - | 51.9x | - | - | 60.0x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 8.7% | 6.6% | 8.4% | 5.2% | 2.5% | 2.8% | 5.3% | 4.7% | 4.5% | -3.3% |
| Revenue CAGR (3y) | 5.3% | 5.7% | 5.2% | 2.3% | 2.2% | -0.3% | 1.4% | 1.3% | 5.8% | -0.5% |
| Revenue CAGR (5y) | 3.0% | 3.2% | 5.7% | 1.7% | 1.4% | 1.1% | 1.3% | 1.9% | 0.8% | 1.5% |
| Gross profit growth (YoY) | 4.4% | 8.1% | 8.2% | 4.5% | 3.9% | 1.6% | 3.4% | 5.3% | 4.5% | -5.6% |
| Operating income growth (YoY) | -11.1% | 5.7% | 13.1% | 19.0% | 11.0% | 0.8% | -4.6% | 6.5% | 12.7% | -10.2% |
| Net income growth (YoY) | -11.7% | 8.2% | -0.2% | 39.7% | -2.1% | 31.7% | 112.9% | 8.2% | -14.9% | -67.4% |
| EPS growth (YoY) | -11.9% | 8.1% | 1.3% | 45.6% | 2.0% | 35.6% | 112.5% | 7.6% | -15.7% | -67.0% |
| EPS CAGR (3y) | -1.1% | 49.5% | 5.0% | 0.7% | -2.8% | 12.6% | 23.6% | 1.7% | 17.9% | -31.8% |
| EPS CAGR (5y) | -1.1% | 24.3% | 17.6% | -0.4% | -6.6% | 4.6% | -3.7% | 1.0% | -5.7% | -26.4% |
| FCF growth (YoY) | - | - | 25.3% | - | - | -10.6% | - | - | -20.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | -17.4% | - | - | -18.1% | - |
| Book value growth (YoY) | -0.8% | 1.3% | -0.1% | -4.4% | -4.6% | -6.3% | -2.5% | 0.7% | -2.8% | -2.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-04-25.
Business segments
$54.38B totalTotal Reportable Segments$33.49B · 61.6%
Medical Surgical$6.50B · 11.9%
Cardiovascular$6.39B · 11.8%
Neuroscience Group$4.97B · 9.1%
Diabetes Group$2.75B · 5.1%
Other Segment$137.00M · 0.3%
All Other Segments$137.00M · 0.3%
Geographic
$62.27B totalTotal Other Countries Excluding Ireland$33.42B · 53.7%
Total Other Countries Excluding United Statesand Ireland$16.25B · 26.1%
International$6.68B · 10.7%
US$5.80B · 9.3%
IE$116.00M · 0.2%
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing Medtronic plc against the 5 most active filers in the same SIC group.
Dividends
$2.84/share trailing 12 months · +1.4% YoY
| Ex-date | Per share |
|---|---|
| Mar 27, 2026 | $0.7100 |
| Dec 26, 2025 | $0.7100 |
| Sep 26, 2025 | $0.7100 |
| Jun 27, 2025 | $0.7100 |
| Mar 28, 2025 | $0.7000 |
| Dec 27, 2024 | $0.7000 |
| Sep 27, 2024 | $0.7000 |
| Jun 28, 2024 | $0.7000 |
| Mar 21, 2024 | $0.6900 |
| Dec 19, 2023 | $0.6900 |
| Sep 21, 2023 | $0.6900 |
| Jun 22, 2023 | $0.6900 |
| Mar 23, 2023 | $0.6800 |
| Dec 20, 2022 | $0.6800 |
| Sep 22, 2022 | $0.6800 |
| Jun 23, 2022 | $0.6800 |
| Mar 24, 2022 | $0.6300 |
| Dec 21, 2021 | $0.6300 |
| Sep 23, 2021 | $0.6300 |
| Jun 24, 2021 | $0.6300 |
| Mar 25, 2021 | $0.5800 |
| Dec 21, 2020 | $0.5800 |
| Sep 24, 2020 | $0.5800 |
| Jun 25, 2020 | $0.5800 |